Published on 03/06/2014
Advanced skin cancer treatments have shown ‘exciting and striking’ results in two international trials.
Drug trials have shown improved survival rates
The trials were presented at the American Society of Clinical Oncology conference in Chicago and both investigations allow tumours to be located and targeted by the body’s immune system.
Experimental drugs permbrolizumab and nivolumab negate the biological process cancers use to disguise themselves from the body’s immune system.
In the past decade survival for advanced melanoma has been as low as six months. Advanced melanoma is where the skin cancer spreads to other organs in the body and can be extremely difficult to treat.
One trial involving more than 400 patients taking pembrolizumab improve survival rates dramatically with 69% of patients surviving at least a year.
Dr David Chao, consultant oncologist at the Royal Free London NHS Foundation Trust, is trialling pembrolizumab on both melanoma and lung cancer patients.
Dr Chao said: “Pembrolizumab looks like it has the potential to be a paradigm shift for cancer therapy.”
The other trial investigated the combination of both nivolumab and an existing immunotherapy ipilimumab. In a small trial of 53 patients, 85% survived after year one and 79% after two years.
Professor of Medical Oncology at Swansea College of Medicine is heavily involved in the trial of these two drugs.
He said: “I am convinced this is a breakthrough in treating melanoma.”
Some health insurance policies can provide comprehensive cancer care and give you access to the latest drugs and treatments available.
© ActiveQuote Ltd. 2014Categories: Health Insurance